Gratuit avec l'essai de 30 jours

  • Malignant

  • How Bad Policy and Bad Evidence Harm People with Cancer
  • Auteur(s): Vinayak K. Prasad
  • Narrateur(s): Vinayak K. Prasad
  • Durée: 7 h et 23 min
  • 4,8 out of 5 stars (6 évaluations)

Choisissez 1 livre audio par mois dans notre incomparable catalogue.
Écoutez à volonté des milliers de livres audio, de livres originaux et de balados.
Accédez à des promotions et à des soldes exclusifs.
L'abonnement Premium Plus se renouvelle automatiquement au tarif de 14,95 $/mois + taxes applicables après 30 jours. Annulation possible à tout moment.
Page de couverture de Malignant

Malignant

Auteur(s): Vinayak K. Prasad
Narrateur(s): Vinayak K. Prasad
Essayer pour 0,00 $

14,95$ par mois après 30 jours. Annulable en tout temps.

Acheter pour 25,00$

Acheter pour 25,00$

Payer avec la carte finissant par
En confirmant votre achat, vous acceptez les conditions d'utilisation d'Audible et la déclaration de confidentialité d'Amazon. Des taxes peuvent s'appliquer.

Description

Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel, but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. 

In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad discusses about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. 

Throughout this audiobook, Prasad illuminates deceptive practices, which:

  • Promote novel cancer therapies long before credible data are available to support such treatment
  • Exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars

Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration. This is a book about how the actions of human beings - our policies, our standards of evidence, and our drug regulation - incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. 

He takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price.

Ultimately, Prasad says:

  • More cancer clinical trials should measure outcomes that actually matter to people with cancer.
  • Patients on those trials should look more like actual global citizens.
  • We need drug regulators to raise, not perpetually lower, the bar for approval.
  • We need unbiased patient advocates and experts.

This well-designed, opinionated, and engaging audiobook explains what we can do differently to make serious and sustained progress against cancer and how we can avoid repeating the policy and practice mistakes of the past.

PLEASE NOTE: When you purchase this title, the accompanying PDF will be available in your Audible Library along with the audio.

©2020 Vinayak K. Prasad (P)2020 Vinayak K. Prasad

Ce que les auditeurs disent de Malignant

Moyenne des évaluations de clients
Au global
  • 5 out of 5 stars
  • 5 étoiles
    5
  • 4 étoiles
    1
  • 3 étoiles
    0
  • 2 étoiles
    0
  • 1 étoile
    0
Performance
  • 5 out of 5 stars
  • 5 étoiles
    5
  • 4 étoiles
    0
  • 3 étoiles
    0
  • 2 étoiles
    0
  • 1 étoile
    0
Histoire
  • 5 out of 5 stars
  • 5 étoiles
    5
  • 4 étoiles
    0
  • 3 étoiles
    0
  • 2 étoiles
    0
  • 1 étoile
    0

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Classer par :
Filtrer
  • Au global
    5 out of 5 stars
  • Performance
    5 out of 5 stars
  • Histoire
    5 out of 5 stars

The best accessible critique of cancer research

The author is clear and straightforward nicely laying out the many problems with industry designing and funding it’s own research to apply more drug approval the a regulator that is clearly captured leading to poor quality evidence of marginal benefit making Billions of dollars for Big Pharma selling drugs for the sake of profiteering rather than benefiting the patient. An eye opener.

Un problème est survenu. Veuillez réessayer dans quelques minutes.

Vous avez donné votre avis sur cette évaluation.

Vous avez donné votre avis sur cette évaluation.